Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

被引：0

作者：

Shibuki, Taro ^{[1
,2
]}

Otsuka, Taiga ^{[3
,4
]}

Shimokawa, Mototsugu ^{[5
,6
]}

Nakazawa, Junichi ^{[7
]}

Arima, Shiho ^{[8
]}

Fukahori, Masaru ^{[9
,10
]}

Miwa, Keisuke ^{[11
]}

Okabe, Yoshinobu ^{[9
]}

Koga, Futa ^{[12
]}

Ueda, Yujiro ^{[13
]}

Kubotsu, Yoshihito ^{[14
]}

Makiyama, Akitaka ^{[15
,16
]}

Shimokawa, Hozumi ^{[15
]}

Takeshita, Shigeyuki ^{[17
]}

Nishikawa, Kazuo ^{[18
]}

Komori, Azusa ^{[18
,19
]}

Otsu, Satoshi ^{[18
]}

Hosokawa, Ayumu ^{[20
]}

Sakai, Tatsunori ^{[21
]}

Oda, Hisanobu ^{[22
]}

Kawahira, Machiko ^{[23
]}

Arita, Shuji ^{[24
]}

Honda, Takuya ^{[25
]}

Taguchi, Hiroki ^{[7
,26
]}

Tsuneyoshi, Kengo ^{[27
]}

Kawaguchi, Yasunori ^{[28
]}

Fujita, Toshihiro ^{[26
]}

Sakae, Takahiro ^{[26
]}

Nio, Kenta ^{[29
,30
]}

Ide, Yasushi ^{[14
,31
]}

Ureshino, Norio ^{[3
,32
]}

Shirakawa, Tsuyoshi ^{[33
,34
]}

Mizuta, Toshihiko ^{[35
]}

Mitsugi, Kenji ^{[29
,30
]}

机构：

[1] Natl Canc Ctr Hosp East, Dept Promot Drug & Diagnost Dev, Div Drug & Diagnost Dev Promot, Translat Res Support Off, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[2] Natl Canc Ctr Hosp East, Dept Hepatobiliary & Pancreat Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan

[3] Saga Ken Med Ctr Koseikan, Dept Med Oncol, 400 Kase Machi, Saga, Saga 8408571, Japan

[4] Minato Med Clin, Dept Internal Med, 3-11-3 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8100072, Japan

[5] Natl Kyushu Canc Ctr, Clin Res Inst, 3-1-1 Notame,Minami Ku, Fukuoka, Fukuoka 8111395, Japan

[6] Yamaguchi Univ, Grad Sch Med, Dept Biostat, 1-1-1 Minamikogushi, Ube, Yamaguchi 7558505, Japan

[7] Kagoshima City Hosp, Dept Gastroenterol, 37-1 Uearata Cho, Kagoshima, Kagoshima 8908760, Japan

[8] Kagoshima Univ, Grad Sch Med & Dent Sci, Digest & Lifestyle Dis, 8-35-1 Sakuragaoka, Kagoshima, Kagoshima 8908520, Japan

[9] Kurume Univ, Dept Med, Div Gastroenterol, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[10] Kyoto Univ Hosp, Kyoto Innovat Ctr Next Generat Clin Trials & iPS C, 54 Kawaharacho,Shogoin,Sakyo Ku, Kyoto 6068507, Japan

[11] Kurume Univ Hosp, Multidisciplinary Treatment Canc Ctr, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan

[12] Saga Med Ctr Koseikan, Dept Hepatobiliary & Pancreatol, 400 Kase Machi, Saga, Saga 8408571, Japan

[13] Japanese Red Cross Kumamoto Hosp, Dept Hematol & Oncol, 2-1-1 Nagamine-Minami,Higashi Ku, Kumamoto, Kumamoto 8618520, Japan

[14] Karatsu Red Cross Hosp, Dept Internal Med, 2430 Watada, Karatsu, Saga 8478588, Japan

[15] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, 1-8-1 Kishinoura,Yahatanishi Ku, Kitakyushu, Fukuoka 8068501, Japan

[16] Gifu Univ Hosp, Canc Ctr, 1-1 Yanagido, Gifu 5011194, Japan

[17] Japanese Red Cross Nagasaki Genbaku Hosp, Dept Gastroenterol, 3-15 Morimachi, Nagasaki, Nagasaki 8528511, Japan

[18] Oita Univ, Fac Med, Dept Med Oncol & Hematol, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan

[19] Natl Hosp Org Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, 160 Minamiumemoto Cho, Matsuyama, Ehime 7910280, Japan

[20] Univ Miyazaki Hosp, Dept Clin Oncol, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan

[21] Natl Hosp Org Kumamoto Med Ctr, Dept Med Oncol, 1-5 Ninomaru,Chuo Ku, Kumamoto, Kumamoto 8600008, Japan

[22] Saiseikai Kumamoto Hosp, Div Integrat Med Oncol, 5-3-1 Oumi,Minami Ku, Kmamoto, Kumamoto 8614193, Japan

[23] Kagoshima Kouseiren Hosp, Dept Gastroenterol, 1-13-1 Yojirou, Kagoshima, Kagoshima 8900062, Japan

[24] Miyazaki Prefectural Miyazaki Hosp, Dept Chemotherapy, Miyazaki, Japan

[25] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki, Nagasaki 8528501, Japan

[26] Saiseikai Sendai Hosp, Dept Gastroenterol, 2-46 Harada Cho, Satsumasendai, Kagoshima 8950074, Japan

[27] Izumi Gen Med Ctr, Dept Gastroenterol, 520 Myoujin Cho, Izumi, Kagoshima 8990131, Japan

[28] Asakura Med Assoc Hosp, Dept Gastroenterol, 422-1 Raiha, Asakura, Fukuoka 8380069, Japan

[29] Sasebo Kyosai Hosp, Dept Med Oncol, 10-17 Shimanji Cho, Sasebo, Nagasaki 8578575, Japan

[30] Hamanomachi Hosp, Dept Med Oncol, 3-3-1 Nagahama,Chuo Ku, Fukuoka, Fukuoka 8108539, Japan

[31] Natl Hosp Org Saga Hosp, Dept Internal Med, 1-20-1 Hinode, Saga, Saga 8498577, Japan

[32] Kimitsu Chuo Hosp, Dept Med Oncol, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan

[33] Eikoh Hosp, 3-8-15 Befu Nishi,Shime Machi, Fukuoka 8112232, Japan

[34] Clin Hematol Oncol Treatment Study Grp, 1-14-6 Muromi Gaoka,Nishi Ku, Fukuoka, Fukuoka 8190030, Japan

[35] Fujikawa Hosp, Dept Internal Med, 1-2-6 Matsubara, Saga, Saga 8400831, Japan

来源：

SCIENTIFIC REPORTS | 2024年 / 14卷 / 01期

关键词：

Pancreatic cancer; Second line; Nanoliposomal irinotecan; S-1; FOLFIRINOX; RANDOMIZED PHASE-II; C-REACTIVE PROTEIN; NAB-PACLITAXEL; 1ST-LINE CHEMOTHERAPY; PLUS GEMCITABINE; SURVIVAL; PROGNOSIS; TRIAL;

D O I：

10.1038/s41598-024-65689-8

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

This study aimed to compare second-line treatment outcomes for patients with unresectable pancreatic cancer previously treated with gemcitabine plus nab-paclitaxel (GnP) therapy. We conducted an integrated analysis of two retrospective studies included 318 patients receiving nanoliposomal irinotecan + 5-fluorouracil/folinic acid (NFF) (n = 102), S-1 (n = 57), or FOLFIRINOX (n = 14) as second-line treatment. Median overall survival (OS) in the NFF group was 9.08 months, significantly better than S-1 (4.90 months, P = 0.002). FOLFIRINOX had a median OS of 4.77 months, not statistically different from NFF. Subgroup analyses of OS indicated NFF was generally superior, however, a statistical interaction was observed between the treatment regimen in serum Alb < 3.5 g/dL (P = 0.042) and serum CRP >= 0.3 mg/dL (P = 0.006). Median progression-free survival (PFS) was 2.93 months for NFF, significantly better than S-1 (2.53 months, P = 0.024), while FOLFIRINOX had a comparable PFS (3.04 months, P = 0.948). Multivariate analysis identified the serum CRP, serum CA19-9, duration of first-line GnP therapy, and use (yes/no) of S-1 for second-line treatment as independent predictors for OS. This study concludes that second-line NFF therapy demonstrated a more favorable OS compared to S-1 therapy, however, it is still important to consider the patient background characteristics while selecting the most appropriate treatment.

引用

页数：10

共 50 条

[21] EFFICACY OF MODIFIED FOLFIRINOX AS SECOND-LINE CHEMOTHERAPY IN METASTATIC PANCREATIC ADENOCARCINOMA AFTER GEMCITABINE PLUS NAB-PACLITAXEL FAILURE
Ikezawa, Kenji
Kiyota, Ryosuke
Takada, Ryoji
Imai, Toshihiro
Yutaro, Abe
Fukutake, Nobuyasu
Takatoshi, Nawa
Katayama, Kazuhiro
Ohkawa, Kazuyoshi
GASTROENTEROLOGY, 2020, 158 (06) : S527 - S527
[22] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
Ide, Yasushi
Otsuka, Taiga
Shimokawa, Mototsugu
Koga, Futa
Ueda, Yujiro
Nakazawa, Junichi
Komori, Azusa
Otsu, Satoshi
Arima, Shiho
Fukahori, Masaru
Makiyama, Akitaka
Shinohara, Yudai
Ueno, Shohei
Taguchi, Hiroki
Honda, Takuya
Shibuki, Taro
Nio, Kenta
Ureshino, Norio
Mizuta, Toshihiko
Mitsugi, Kenji
Shirakawa, Tsuyoshi
ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
[23] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
Chae, Heejung
Jeong, Hyehyun
Cheon, Jaekyung
Chon, Hong Jae
Ryu, Hyewon
Kim, Il-Hwan
Kang, Myoung Joo
Jeong, Jae Ho
Ryoo, Baek-Yeol
Kim, Kyu-pyo
Yoo, Changhoon
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
[24] Erratum: Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
E Gabriela Chiorean
Daniel D Von Hoff
Josep Tabernero
Robert El-Maraghi
Wen Wee Ma
Michele Reni
Marion Harris
Robert Whorf
Helen Liu
Jack Shiansong Li
Victoria Manax
Alfredo Romano
Brian Lu
David Goldstein
British Journal of Cancer, 2016, 115 : e13 - e13
[25] A phase-I study of second-line S-IROX for unresectable pancreatic cancer after gemcitabine plus nab-paclitaxel failure
Okuno, Mitsuru
Mukai, Tsuyoshi
Iwata, Keisuke
Takagi, Akihiro
Ito, Yuki
Ohashi, Yosuke
Tezuka, Ryuichi
Iwasa, Yuhei
Iwata, Shota
Tomita, Eiichi
MEDICAL ONCOLOGY, 2024, 41 (08)
[26] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
Yamamoto, Shun
Ueno, Hideki
Tanaka, Midori
Inagaki, Yuji
Ohba, Akihiro
Sakamoto, Yasunari
Kondo, Shunsuke
Morizane, Chigusa
Okusaka, Takuji
ANNALS OF ONCOLOGY, 2017, 28
[27] Second-line treatment with modified FOLFIRINOX in patients with pancreatic adenocarcinoma who have failed first-line treatment with gemcitabine and nab-paclitaxel
McSweeney, T.
Das, A.
O'Mahony, A.
O'Tighearnaigh, F.
O'Byrne, L.
Feely, M.
Passmore, E.
Keane, S.
Lanigan, S.
Fitzgerald, S.
Browne, T.
De Beer, V.
Dean, A.
ANNALS OF ONCOLOGY, 2023, 34 : S133 - S133
[28] Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response
Nguyen, Khanh T.
Kalyan, Aparna
Beasley, H. Scott
Singhi, Aatur D.
Sun, Weijing
Zeh, Herbert J.
Normolle, Daniel
Bahary, Nathan
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (03) : 556 - 565
[29] FOLFIRINOX and gemcitabine/nab-paclitaxel efficacy in the treatment of locally advanced unresectable pancreatic adenocarcinoma.
Bednar, Filip
Ocuin, Lee Mayer
Steve, Jennifer
Zenati, Mazen S.
Winters, Sharon
Hogg, Melissa Ellen
Bahary, Nathan
Zeh, Herbert J.
Zureikat, Amer H.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[30] FOLFIRINOX and gemcitabine plus nab-paclitaxel as second-line or later chemotherapy and for locally advanced disease
Maeda, Osamu
Yokoyama, Yukihiro
Ando, Yuichi
ANNALS OF ONCOLOGY, 2016, 27

← 1 2 3 4 5 →